Skip to main content
  • Sign in
    Welcome !
    My account
    Logout

10x Genomics, Inc. (TXG) Stock Forecast 2025 - AI Price Prediction & Analysis

10x Genomics, Inc. (TXG) AI Stock Price Forecast & Investment Analysis

10x Genomics, Inc. Stock Price Chart and Technical Analysis

Loading 10x Genomics, Inc. interactive price chart and technical analysis...

10x Genomics, Inc. (TXG) - Comprehensive Stock Analysis & Investment Research

Company Overview & Business Profile

10x Genomics, Inc. (Stock Symbol: TXG) is a leading company in the Industrial Applications and Services sector , specifically operating within the Laboratory Analytical Instruments industry. The organization employs approximately 500 professionals worldwide . The company has established itself as an emerging investment opportunity with substantial growth potential.

Financial Performance & Key Metrics Analysis

Annual Revenue: $644 million generating a -247.1% net profit margin .

Market Capitalization: $1659 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -11.4% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Advanced AI Stock Prediction & Price Target Analysis

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for 10x Genomics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Market Position & Competitive Advantage Analysis

10x Genomics, Inc. strategically competes in the highly dynamic Laboratory Analytical Instruments marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities . The company maintains a healthy 583.1% gross margin, indicating strong pricing power and operational efficiency.

10x Genomics, Inc. (TXG) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for 10x Genomics, Inc. stock analysis.

Loading 10x Genomics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into 10x Genomics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if 10x Genomics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For 10x Genomics, Inc.: With a P/E ratio of -8.57, the market sees the stock as potentially undervalued.

P/E Ratio -8.57x
P/B Ratio 2.15x
Market Cap $1659M
EPS $-0.70
Book Value/Share $6.22
Revenue/Share $5.19
FCF/Share $-1.05
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently 10x Genomics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For 10x Genomics, Inc.: An ROE of -11.4% indicates room for improvement in shareholder value creation.

ROE -11.4%
ROA -9.1%
ROIC -10.3%
Gross Margin 583.1%
Operating Margin -278.0%
Net Margin -247.1%
EBT Margin -16.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess 10x Genomics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For 10x Genomics, Inc.: A current ratio of 7.38 indicates strong liquidity.

Current Ratio 7.38x
Quick Ratio 6.52x
D/E Ratio 0.12x
Financial Leverage 1.24x
Interest Coverage -108.1x
Working Capital $656M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal 10x Genomics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For 10x Genomics, Inc.: Free cash flow of $-129M indicates cash challenges that need attention.

Operating Cash Flow $-38M
Free Cash Flow $-129M
Capital Spending $-91M
FCF/Sales -25.8%
CapEx/Sales 18.1%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively 10x Genomics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For 10x Genomics, Inc.: An asset turnover of 0.51x suggests room for improvement in asset utilization.

Asset Turnover 0.51x
Receivables Turnover 7.5x
Inventory Turnover 1.6x
Fixed Assets Turnover 2.3x
Days Sales Outstanding 49 days
Days Inventory 226 days
Payables Period 76 days
Cash Conversion Cycle 199 days
Understanding Financial Statement Data

What these metrics mean: Key figures from 10x Genomics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For 10x Genomics, Inc.: With annual revenue of $644M, 10x Genomics, Inc. demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $644M
R&D Expense $47M
SG&A Expense $54M
Cost of Goods Sold $223M
Balance Sheet Highlights ($ Millions)
Total Current Assets $70M
Cash & Short-term Investments $54M
Total Liabilities $20M
Short-term Debt $2M
Accounts Receivable $8M
Inventory $6M
Dividend & Shareholder Information
Shares Outstanding 124M
Growth Metrics (YoY)
EPS Growth -10.5%

Latest 10x Genomics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting 10x Genomics, Inc. (TXG) stock price and investment outlook.

, source: CNN

View 10x Genomics Inc Class A TXG stock quote prices, financial information, real-time forecasts, and company news from CNN.

, source: The Victoria Advocate

PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March ...

, source: Seeking Alpha

10x Genomics, Inc. (NASDAQ: TXG) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Cassie Corneau - Director of Investor Relations & Strategic Finance Serge Saxonov ...

, source: BioWorld

10x Genomics Inc. launched its latest platform for single-cell analysis, the Chromium X Series, to cost-effectively "enable massively large-scale experiments," according to the company.

, source: Morningstar

PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to acquire ...

10x Genomics, Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of 10x Genomics, Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
A Unlock Forecast $35688M 29.3x 5.6x
AKYA Unlock Forecast $64M -2.1x -10.9x
ASTC Unlock Forecast $9M 28.9x 0.4x
AVTR Unlock Forecast $9064M 13.2x 1.4x
AXDX Unlock Forecast $0M -0.2x 0.0x
BIO Unlock Forecast $8020M 25.1x 1.1x
BIO-B Unlock Forecast $6816M 21.4x 1.0x
BNGO Unlock Forecast $15M 0.0x 0.3x
BRKR Unlock Forecast $6145M 28.3x 3.2x
CTKB Unlock Forecast $528M 82.0x 1.4x
EYPT Unlock Forecast $827M -4.4x 3.4x
HBIO Unlock Forecast $22M -8.3x 1.4x
ILMN Unlock Forecast $15456M 12.3x 6.8x
LAB Unlock Forecast $481M -2.4x 1.1x
LCTC Unlock Forecast $9M x 1.5x
MTD Unlock Forecast $24913M 31.5x -136.9x
NAUT Unlock Forecast $86M -3.8x 0.5x
OMIC Unlock Forecast $50M -1.7x 0.4x
PACB Unlock Forecast $393M -1.5x 6.4x
PRPO Unlock Forecast $22M -1.2x 0.6x
QTRX Unlock Forecast $209M -11.1x 0.7x
RPID Unlock Forecast $107M -0.9x 2.0x
RVTY Unlock Forecast $10446M 36.6x 1.4x
SEER Unlock Forecast $130M -2.0x 0.4x
TXG Unlock Forecast $1659M -8.6x 2.2x
WAT Unlock Forecast $17696M 26.8x 8.2x

Frequently Asked Questions - 10x Genomics, Inc. Stock Forecast

How accurate are 10x Genomics, Inc. stock predictions?

Our AI model demonstrates 63% historical accuracy for TXG predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence 10x Genomics, Inc. stock price forecasts?

Our analysis considers 10x Genomics, Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is 10x Genomics, Inc. a good investment in 2025?

Based on our AI analysis, 10x Genomics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are 10x Genomics, Inc. forecasts updated?

10x Genomics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced 10x Genomics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for 10x Genomics, Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...